



KDL BIOTECH LIMITED


Registered Office & Works : Village Savroli, Tal. Khalapur, Dist. Raigad, Maharashtra - 410 202.

Part I

Statement of Standalone Unaudited Results for the Quarter / Nine Months Ended 31/12/2012

(in lakhs)

Particulars	3 Months ended (31/12/2012)	3 Months ended (30/09/2012)	Corresponding 3 Months ended in the previous year (31/12/2011)	9 Months ended in the current year (31/12/2012)	9 Months ended in the previous year (31/12/2011)	Previous year ended (31/03/2012)
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Income from Operations						
(a) Net Sales/Income from Operations (Net of excise duty)	127.47	167.14	297.92	463.02	575.11	850.22
(b) Other Operating Income (Job Work Charges Received)	272.01	490.13	490.92	1,078.07	1,541.25	1,796.35
Total income from Operations (net)	399.48	657.27	788.84	1,541.09	2,116.36	2,646.57
2. Expenses						
a. Cost of Materials consumed	23.55	55.84	4.46	82.66	28.34	46.64
b. Purchase of stock-in-trade	111.27	106.89	108.17	330.82	307.31	423.51
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(38.16)	-	-	(38.16)	-	-
d. Employee benefits expenses	166.52	262.82	236.43	669.27	720.98	964.94
e. Depreciation and amortisation expense	171.85	174.18	248.62	517.99	743.23	913.29
f. Other expenses	207.71	272.57	352.54	749.24	1,059.69	1,418.12
Total Expenses	642.74	872.30	950.22	2,311.82	2,859.55	3,766.50
3. Profit/ (Loss) from Operations before other income, finance costs and exceptional items (1-2)	(243.26)	(215.03)	(161.38)	(770.73)	(743.19)	(1,119.93)
4. Other Income	7.95	7.96	12.25	24.15	33.69	75.84
5. Profit/ (Loss) from ordinary activities before finance costs and exceptional items (3+4)	(235.31)	(207.07)	(149.13)	(746.58)	(709.50)	(1,044.09)
6. Finance Costs	172.46	172.51	169.72	513.63	505.03	677.15
7. Profit/ (Loss) from ordinary activities after finance costs but before exceptional items (5+6)	(407.77)	(379.58)	(318.85)	(1,260.21)	(1,214.53)	(1,721.24)
8. Exceptional Items	-	-	-	-	-	-
9. Profit / (Loss) from ordinary activities before tax (7+8)	(407.77)	(379.58)	(318.85)	(1,260.21)	(1,214.53)	(1,721.24)
10. Tax expense	-	-	-	-	-	-
11. Net Profit / (Loss) from ordinary activities after tax (9-10)	(407.77)	(379.58)	(318.85)	(1,260.21)	(1,214.53)	(1,721.24)
12. Extraordinary Items	-	-	-	-	-	-
13. Net Profit / (Loss) for the period (11-12)	(407.77)	(379.58)	(318.85)	(1,260.21)	(1,214.53)	(1,721.24)
14. Paid-up equity share capital (Face Value of Rs. 10 each)	2,403.52	2,403.52	2,403.52	2,403.52	2,403.52	2,403.52
15. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						
16.i Earnings Per Share (before extraordinary items) (Face Value of 10/- each) (not annualised)						
(a) Basic	(1.70)	(1.58)	(1.33)	(5.24)	(5.05)	(7.16)
(b) Diluted	(1.70)	(1.58)	(1.33)	(5.24)	(5.05)	(7.16)
16.ii Earnings Per Share (after extraordinary items) (Face Value of 10/- each) (not annualised)						
(a) Basic	(1.70)	(1.58)	(1.33)	(5.24)	(5.05)	(7.16)
(b) Diluted	(1.70)	(1.58)	(1.33)	(5.24)	(5.05)	(7.16)



KDL BIOTECH LIMITED

Registered Office & Works : Village Savroli, Tal. Khalapur, Dist. Raigad, Maharashtra - 410 202
Tel : 02192 - 274 026 to 274 028 • Fax : 02192 - 274 031


Part II
Selected Information for the Quarter / Nine Months Ended 31/12/2012

Particulars	3 Months ended (31/12/2012)	3 Months ended (30/09/2012)	Corresponding 3 Months ended in the previous year (31/12/2011)	9 Months ended in the current year (31/12/2012)	9 Months ended in the previous year (31/12/2011)	Previous year ended (31/03/2012)
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
A. PARTICULARS OF SHAREHOLDING						
1. Public shareholding						
- Number of shares	7,485,241	7,485,241	7,485,241	7,485,241	7,485,241	7,485,241
- Percentage of shareholding	31.14%	31.14%	31.14%	31.14%	31.14%	31.14%
2. Promoters and Promoter Group Shareholding						
a) Pledged / Encumbered						
- Number of shares	-	-	-	-	-	-
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	-	-	-	-	-	-
- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
b) Non - Encumbered						
- Number of shares	16,549,910	16,549,910	16,549,910	16,549,910	16,549,910	16,549,910
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100%	100%	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the company)	68.86%	68.86%	68.86%	68.86%	68.86%	68.86%
B. INVESTOR COMPLAINTS						
Pending at the beginning of the quarter		0				
Received during the quarter		1				
Disposed of during the quarter		1				
Remaining unresolved at the end of the quarter		0				

NOTES

- The above un-audited results have been reviewed by the Audit Committee and approved and taken on record by the Board of Directors in their meeting held on February 13, 2013.
 - Employee benefits expenses is net of reversal of Rs. 37.46 lakhs of excess provision made in Quarter ended 30th September, 2012.
 - Previous year / period figures have been regrouped or reclassified wherever necessary to make them comparable with the figures of the current period.
 - The Company has only one segment of activity namely, "Pharmaceuticals", accordingly disclosure requirements under AS-17 for segmental information is not applicable.
 - The Company had submitted revised One Time Settlement (OTS) proposal on March 01, 2012 to the bankers which is pending.
 - State Bank of India on behalf of itself and other consortium member banks, has issued notice dated April 10, 2012 u/s 13(2) of the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest (SARFESI) Act, 2002 to the company and the company has replied to the said notice.
 - The Company had made reference with BIFR on June 06, 2011. The case was registered with the BIFR for determination of status of company's sickness and at the hearing held on 26-11-2012, the BIFR has passed the order holding that the Company's reference based on balance sheet as on 31-03-2010 is not maintainable and accordingly the said reference was rejected as dismissed.
- The Company has once again filed reference with BIFR on 29-11-2012 based on balance sheet as on 31-03-2012. The BIFR vide letter dated 15.01.2013 has informed the Company that the reference has been registered with Board as case No. 04/2013 and the Company is restrained from disposing of or alienating in any manner any fixed assets of the Company without the consent of the Board.
- The Bankers have filed suit before Debt Recovery Tribunal (DRT), Mumbai towards recovery of outstanding dues DRT has stayed the matter in view of the reference made by the Company to BIFR.
 - The Company has not provided for the penal interest and additional interest on defaults in payment of installments and interest on credit facilities from banks the amount of which is unascertained. The auditors have qualified their limited review report for this matter. The Company's management believes that pending finality of the reference filed with BIFR as well as OTS proposal, no penal interest and additional interest needs to be accrued on the loans at this point of time.

Place : Vapi
Dated : 13.02.2013



For and on behalf of the Board of Directors

Dr. Rajesh Agrawal
Dr. Rajesh Agrawal
(Director - Technical)

KDL BIOTECH LIMITED

Registered Office & Works : Village Savroli, Tal. Khasara, Khopoli, Dist. Raigad, Maharashtra - 410 202
Tel: 02192 - 274 026 to 274 028 • Fax: 02192 - 274 031